Defining and Controlling Severe Familial Hypercholesterolemia
|
|
- Herbert Lawrence
- 6 years ago
- Views:
Transcription
1 Defining and Controlling Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD InCor-University of Sao Paulo Hospital Israelita Albert Einstein Brazil 1
2 Disclosure Honoraria received for consulting, speaker or researcher activities : Astra Zeneca, Amgen, Boehringer-Ingelheim, Cerenis, Eli Lilly, Genzyme, Kowa, Pfizer, Sanofi/Regeneron. 2
3 Familial Hypercholesterolemia: Need for Risk Stratification Elevated lifetime risk of cardiovascular disease However, heterogeneity in this risk LDL levels Other risk factors Susceptibility= subclinical disease Newer treatments PCSK9 inhibitors 6-14,000 US dollars year Mipomersen/Lomitapide US ,000 year
4 Higher LDL-C = Greater Risk
5 Cumulative LDL-C (mmol) Coronary disease & death before age 20 Untreated coronary disease before age 55/60 HOZ Untreated Treat at 10yrs Non FH Treat at 18yrs Homozygous FH Heterozygous FH yrs Start low dose statin Threshold for CHD Start high dose statin 35yrs 48yrs 53yrs 55yr Female sex Smoking Hypertension Diabetes Triglycerides HDL-C Lipoprotein(a) 50 0 Without FH Age in years Years Age Adapted from Horton et al.
6 CVD risk vs. non severe FH 1.25 [95% CI: ], p= Besseling et al. Atherosclerosis 2014;
7 Overlap in LDL-C Between Homozygous and Heterozygous FH
8 Number of patients Distribution of serum total cholesterol levels in normal subjects, and heterozygous and homozygous FH patients Normal Heterozygous FH Homozygous FH (100) 5.2 (200) 7.8 (300) 10.3 (400) 12.9 (500) 15.5 (600) 18.1 (700) Serum cholesterol mmol/l (mg/dl) 20.7 (800) 23.3 (900) 25.8 (1000) Harada-Shiba et al. J Atheroscler Thromb 2012;19:
9 Molecular Defect and LDL-C Phenotype Santos RD et al Lancet Diab Endocrinol 2016;4:
10 Other Risk Factors The usual suspects
11 Risk factors for CHD in Genotyped FH Patients Besseling et al. Atherosclerosis 2014;
12 jou r n al h o m ep ag e: w w w.el sev i er.co m /l o cat e/at h er o scl er o si s Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia P~amela R.S. Silva a, *, Cinthia E. Jannes a, Julia D.C. Marsiglia a, Jose E. Krieger a, Raul D. Santos b, Alexandre C. Author's Pereira a Personal Copy 148 a Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of S~ao Paulo Medical School Hospital, S~ao Paulo, Brazil Index Cases b Lipid Clinic, Heart Institute (InCor), University ofp.r.s. S~ao Silva Paulo et Medical al. / Atherosclerosis School Hospital, 250 (2016) S~ao144e150 Paulo, Brazil Table 5 Variables associated w ith CV events in index cases presenting or not mutations after univariate and multivariate logistic regression. a r t i c l e i n f o a b s t r a c t OR a 95%CI p value c OR b 95%CI p value Mutation Article þ history: 4.35 Background 1.45e and aims: This0.01 study reports the first year follow - up of individuals enrolled in Brazil s Age (years) Received 17 March e cascade screening program for Famili al Hypercholester olemi a (FH), Hipercol Brasil. Predict ors Gender (male) e Received in revised form Hypertension 1.28 occur rence 0.50e 3.27 of cardiovascular 0.59(CV) events in individuals screened for FH w ere studied. Methods: Th 9 May 2016 Previous CVD 2.75 open prospective 1.17e 6.43 cohor t of0.01 individuals who w ere included in a cascade genetic screening program Accepted 11 May 2016 Tobacco consumption (current and former) 0.87 The first 0.34e prospective 2.25 follow0.77 -up w as carried out one year after patien ts received their genetic test Family Available history of online CVD 15 May e Individuals included in this study w ere index cases (probands) and relatives w ith identi fied (M þ ) Xanthelasmas e Corneal genetic mutation s (M ). Logistic regression analysis w as perform ed to determine predictive va Keywords: arcus e e Tendon xanthomas 2.93 for the0.76e occurrence of CV events 0.11 censored at one-year of follow - up. Familial hypercholest erolemia TC 1.00 Cascade screening Results: 0.99e A total 1.01 of 818 subjects 0.88 w ere included, 47 first CV events w ere ascertained, w ith 14 (29.7% LDL-C e Cardiovascular diseases fatal. For index cases, the only factor independently associated w ith increased risk of CV events w HDL-C e e TG Cardiovascular disease predictors 1.00 presence 0.99e of1.01 corneal arcus 0.20 (OR: 9.39; 95%CI: 2.46e 35.82). There w as an inverse association of CV Index patient w ith higher HDL-cholesterol levels (OR: 0.95; 95%CI: 0.90e 0.99). For M þ relatives, risk factors ass a Univariate Logistic Regression Analysis. b Multivariate Logistic Regression Analysis (Adjusted for age, gender, w ithhdl-c, increased corneal CV arcus, events previous risk CVD). w ere diabetes mellitus (OR: 7.97; 95%CI: 2.07e 30.66) and tobacc c p value < sumption (OR: 3.70; 95%CI: 1.09e 12.50). Conclusions: A high one-year incidence of CV events w as found in this cascade-screening coho dictors of events differed bet w een index cases and relatives and can be useful for the developm Table 6 preventive efforts in this highly susceptible group of individuals. Variables associated w ith CV events in relatives w ith positive mutations after univariate and multivariate logistic regression. Silva P et al. Atherosclerosis 2016;250: Elsevier Ireland Ltd. All rights re OR a 95%CI p value c OR b 95%CI p value
13 Mutation þ e Age (years) e Gender (male) e Hypertension e Previous CVD e Tobacco consumption (current and former) e Family history of CVD e Xanthelasmas Predictors of cardiovascular e events 8.86 after 0.10 one year of molecular Corneal arcus e e Tendonscreening xanthomas for Familial 2.93hypercholesterolemia 0.76e TC e LDL-C e HDL-CP~amela R.S. Silva a, *, Cinthia 0.95 E. Jannes a 0.91e 0.99, Julia D.C. 0.01Marsiglia 0.95, Jose E. 0.90e Krieger a 0.99, 0.04 TG e Raul D. Santos b, Alexandre C. Pereira a a Univariate Logistic Regression Analysis. b Multivariate a Laboratory LogisticofRegression Genetics and Analysis Molecular (Adjusted Cardiology, for age, gender, Heart HDL-C, Institute corneal (InCor), arcus, University previous CVD). of S~ao Paulo Medical School Hospital, S~ao Paulo, Brazil c p value b Lipid < Clinic, Heart Institute (InCor), University of S~ao Paulo Medical School Hospital, S~ao Paulo, Brazil Table 6 Variables associated w ith CV events in relatives w ith positive mutations after univariate and multivariate logistic regression. a r t i c l e i n f o jou r n al h o m ep ag e: w w w.el sev i er.co m /l o cat e/at h er o scl er o si s Relatives a b s t r a c t OR a 95%CI p value c OR b 95%CI p value Article history: Background and aims: This study reports the first year follow - up of individuals enrolled in Brazil s Age (years) e Received 17 March 2016 Gender (male) 3.14 cascade 1.13e screening 8.70 program 0.02 for Famili al Hypercholester olemi a (FH), Hipercol Brasil. Predict ors Received in revised form Hypertension 4.41 occur 1.58e rence of cardiovascular 0.01 (CV) events in individuals screened for FH w ere studied. Methods: Th Diabetes 9 May open3.65e prospective cohor0.01 t of individuals w7.97 ho w ere included 2.07e in a cascade genetic 0.01 screening program Previous Accepted CVD 11 May e The first prospective follow -up w as carried out one year after patien ts received their genetic test TobaccoAvailable consumption online (current 15 May and 2016 former) e e Family history of CVD 0.67 Individuals 0.22e 2.00 included in 0.47 this study w ere index cases (probands) and relatives w ith identi fied (M þ ) Xanthelasmas 1.37 genetic 0.29emutation 6.37 s (M 0.68 ). Logistic regression analysis w as perform ed to determine predictive va Keywords: Corneal arcus 4.03 for the 1.40eoccurrence of CV 0.01events censored at one-year of follow - up. Familial hypercholest erolemia Tendon xanthoma e TC Cascade screening Results: A total of 818 subjects w ere included, 47 first CV events w ere ascertained, w ith 14 (29.7% e LDL-C Cardiovascular diseases fatal. For index cases, the only factor independently associated w ith increased risk of CV events w e HDL-C Cardiovascular disease predictors 0.97 presence 0.93e 1.02 of corneal arcus 0.28(OR: 9.39; 95%CI: 2.46e 35.82). There w as an inverse association of CV TG Index patient 0.99 w ith0.97e higher 1.01 HDL-cholesterol 0.99 levels (OR: 0.95; 95%CI: 0.90e 0.99). For M þ relatives, risk factors ass a Univariate Logistic Regression Analysis. w ith increased CV events risk w ere diabetes mellitus (OR: 7.97; 95%CI: 2.07e 30.66) and tobacc b Multivariate Logistic Regression Analysis (Adjusted for age, hypertension, sumption diabetes, (OR: previous 3.70; CVD, 95%CI: tobacco 1.09e consumption 12.50). and corneal arcus). c p value < Conclusions: A high one-year incidence of CV events w as found in this cascade-screening coho dictors of events differed bet w een index cases and relatives and can be useful for the developm preventive efforts in this highly susceptible group of individuals. nonfatal CV events in the first year of follow -up w as more than individuals [18e 21]. Indeed, xanthelasmas and corneal arcus formation, important markers of long term exposition to high Silva P et al. Atherosclerosis 2016;250: Elsevier Ireland Ltd. All rights re tw ice in M þ IC than in affect ed relatives. The occurrence of coro- levelsof
14 Lipoprotein(a) Levels in Familial Hypercholesterolemia : An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation Figure 4 Kaplan-Meier Curves for CVD-Free Survival in Subjects With FH According to Lp(a) Levels and Type of Mutation The black solid line indicates null mutations and Lp(a) levels >50 mg/dl; the black dashed line indicates null mutations and Lp(a)... Alonso R et al. Journal of the American College of Cardiology, Volume 63, Issue 19, 2014,
15 Lp(a), FH and Myocardial Infarction Risk : Prospective Data Langested A et al. Lancet Diabetes Endocrinol Jul;4(7):577-87
16 Secondary vs. Primary Prevention
17 Secondary vs. Primary Prevention in FH and Mortality in the UK: Effects of Statins N=3382 patients (FUP ) 370 deaths Standardized mortality ratios All aged years CHD mortality reduced by 37% (95% CI 7 56) from 3.4 to 2.1-fold excess. Primary prevention: 48% reduction in CHD mortality from 2.0-fold excess to none Secondary prevention: 25% reduction in CHD mortality from 5.2 (95% CI ) to a 3.9-fold excess (95% CI ) Neil et al Eur Heart J 2008; 29:
18 Incidence of recurrent coronary events in young patients with premature coronary heart disease by presence of familial hypercholesterolemia (FH; n=1369). All Acute Coronary Syndrome Nanchen D et al. Circulation. 2016;134:
19 Advanced Subclinical Coronary Atherosclerosis
20 Subclinical Coronary Atherosclerosis in FH Figure 2 A CAC= 40, 90 th % B Rocha,VZ Santos RD J Am Coll Cardiol May 28;61(21):
21 Gidding S et al. Circulation. 1998;98:
22 Mangili LC et al. Atherosclerosis 2016 in press
23 FH mutation as a risk factor?
24 Risk of Coronary Artery Disease in those with Elevated LDL cholesterol ( 190 mg/dl) According to Familial Hypercholesterolemia Mutation Status LDL-C> 190 mg/dl FH mutation- FH Mutation+ LDL-C < 130 and FH mutation - N CAD free controls/n CAD Case 1264 (422/842) 73 ( 8/65) 7485 (5175/2310) OR for CAD (95% CI) 6.0 ( ) P< ( ) P<0.001 Reference P FH mutation+ vs. - LDL-C adjusted OR for CAD (95%CI) ( ) p< ( ) P<0.001 Reference P FH mutation + vs Adapted from Khera A et al. JACC online 3 April 2016 doi /j.jacc
25 Santos RD et al Lancet Diab Endocrinol 2016;4:
26 Risk Conditions to Consider Older > 40 years old without treatment Smoking, Male gender Lp(a)>50 mg/dl Low-HDL-C (<1mmol/L or 40 mg/dl), Hypertension Diabetes mellitus Family history of early cardiovascular disease in first degree relatives (<55 years old in males and < 60 years old in females) Chronic kidney disease (defined as an estimated glomerular filtration rare < 60 ml/min/1.73 m 2 BMI >30 kg/m 2 Santos RD et al Lancet Diab Endocrinol 2016;4:
27 Severe Familial Hypercholesterolemia-IAS At presentation (untreated LDL-C) LDL C >10 mmol/l (400 mg/dl) LDL-C >8.0 mmol/l (310 mg/dl) + one high risk condition LDL-C > 5 mmol/l (190 mg/dl) + two high risk conditions Realistic goal: reduce 50% LDL-C Ideal goal: LDL-C < 2.5 mmol/l (100 mg/dl) With subclinical atherosclerosis assessment Advanced subclinical atherosclerosis Coronary: A-Coronary artery calcium (CAC) score > 100 Agatston units, or > 75 th percentile for age and gender* Realistic goal: reduce 50% Ideal goal : LDL-C < 1.8 mmol/l (70 mg/dl) B-Computed tomography angiography (CTA) with obstructions > 50% or presence of nonobstructive plaques > one vessel. Presence of clinical atherosclerotic cardiovascular disease Realistic goal: reduce LDL- C 50% Ideal goal: LDL-C < 1.8 mmol/l (70 mg/dl) Santos RD et al Lancet Diab Endocrinol 2016;4:
28 Treatment
29 Heterozygous FH New Horizons: PCSK9 Inhibitors LDL-C values < 1.8 mmol/l (70 mg/dl) in refractory FH patients Rutherford % treated with evolocumab Odyssey FH I and II % in those receiving alirocumab 1-Raal et al. Lancet 2015; 385: Kastelein et al. Eur Heart J 2015; 36:
30 Treatment Algorithm Santos RD et al Lancet Diab Endocrinol 2016;4:
31 Conclusions: Severe Familial Hypercholesterolemia Elevated lifetime risk of cardiovascular disease However, heterogeneity in this risk LDL levels Other risk factors Susceptibility= subclinical disease Previous CVD Identify highest risk patients in order to have best treatment cost-effectiveness
Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil
Defining Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD Brazil 1 Disclosure Honoraria received for consulting, speaker and or researcher activities : Astra Zeneca, Akcea, Amgen, Biolab, Esperion,
More informationFH: Vision of the International Atherosclerosis Society. Raul D. Santos MD, PhD Sao Paulo, Brazil
FH: Vision of the International Atherosclerosis Society Raul D. Santos MD, PhD Sao Paulo, Brazil 1 Declaration I have received honoraria related to consulting, talks or research from : Akcea, Amgen, Astra
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationFamilial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
More informationHomozygous Familial Hypercholesterolemia: phenotype rules! Commentary on the study of Raal et al.
Homozygous Familial Hypercholesterolemia: phenotype rules! Commentary on the study of Raal et al. Raul D. Santos Lipid Clinic Heart Institute (InCor) University of Sao Paulo Medical School Hospital and
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationTreatment of severe Familial Hypercholesterolemia LDL Apheresis
Treatment of severe Familial Hypercholesterolemia LDL Apheresis Identifying and Treating Severe Familial Hypercholesterolemia October 14-15, 2017 Dubai, UAE Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationDepartment of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan. 4
146 Journal of Atherosclerosis and Thrombosis Original Articles Vol. 11, No. 3 Clinical Features of Familial Hypercholesterolemia in Japan in a Database from 1996 1998 by the Research Committee of the
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationFamilial Hypercholesterolemia: A model of Preventive Medicine
Familial Hypercholesterolemia: A model of Preventive Medicine Pedro Mata MD, PhD Spanish FH Foundation Iberoamerican FH Network www.colesterolfamiliar.org Time to Focus on Non Communicable Diseases (NCDs)
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationPCSK9 Inhibitors: A View of Clinical Studies
PCSK9 Inhibitors: A View of Clinical Studies Slide deck kindly donated for website use by Professor Raul D. Santos Lipid Clinic InCor-HCFMUSP Sao Paulo, Brazil PCSK9 Inhibitors : A View of Clinical Studies
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationCCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018
CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update November 17 th, 2018 Faculty/Presenter Disclosure Faculty: Rick Ward Relationships with commercial interests: Grants/Research Support:
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationDistinguishing FH from non-fh: Right therapy, right patient, right time. Joshua W. Knowles, MD, PhD Stanford and the FH Foundation
Distinguishing FH from non-fh: Right therapy, right patient, right time Joshua W. Knowles, MD, PhD Stanford and the FH Foundation Disclosures Role as CMA of the FH Foundation is not compensated. www.thefhfoundation.org
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationCascade Screening for FH: the U.S. experience
Cascade Screening for FH: the U.S. experience Paul N. Hopkins, MD, MSPH Professor of Internal Medicine Cardiovascular Genetics University of Utah Disclosures Consultant Genzyme, Amgen, Regeneron Research
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationFocus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013 Conflicts CMO for The FH Foundation Pre-talk quiz What is cascade screening? 1. screening all family members 2.
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationWORKSHOP 1. Management of Patients with Familial Hypercholesterolemia
WORKSHOP 1 Management of Patients with Familial Hypercholesterolemia Tutors: Manal Al-Kindi (Oman)/ Gilles Lambert (France) (Case 1) Zuhier Awan (KSA)/ Raul Santos (Brazil) (Case 2) Khalid Al-Waili (Oman)/
More informationNephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler
Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9- Inhibitors, Lipoprotein Apheresis or
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationFamilial Hypercholesterolemia What a cardiologist should know
Institut für Klinische Chemie Arnold von Eckardstein Familial Hypercholesterolemia What a cardiologist should know Etiology of Hypercholesterolemia monogenic: (rare): e.g. familial hypercholesterolemia
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More information*Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
Tuesday, May 26, 2015 Clinical Breakthroughs: Modifying LDL Cholesterol to Prevent CV Events International Society of Atherosclerosis, Amsterdam, Netherlands Long-term Treatment With Evolocumab in Patients
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationPresenter Disclosure Information
1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationWho Cares About the Past?
Risk Factors, the New Calcium Score, Rheology and Atherosclerosis Progression Arthur Agatston 2/21/15 The Vulnerable Plaque vs. Plaque Burden CT Angiogram Is There a Role for Coronary Artery Calcium Scoring
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationConceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.
Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management None Disclosures Arthur Agatston Conceptual Approach to CAD Risk Devereux Circulation, 1993 1 Age Obesity Family Hx Diabetes
More informationCoronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute
Coronary Artery Calcium Vimal Ramjee, MD FACC The Chattanooga Heart Institute Disclosures I have no conflicts of interest to disclose. Objectives Recognize the utility of coronary artery calcium scoring
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationResults of the GLAGOV Trial
Results of the GLAGOV Trial Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound Steven E. Nissen MD Stephen J. Nicholls MBBS PhD Consulting: Many companies
More informationDYSLIPIDEMIA. Michael Brändle, Stefan Bilz
DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention
More informationLIPOPROTIEN APHERESIS. Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center
LIPOPROTIEN APHERESIS Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center OUTLINE Familial Hypercholesterolemia (FH) Diagnosis Treatment options Lipoprotein apheresis Procedures Expected
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationProblem patients in primary care Patient 4: Peripheral artery disease
Problem patients in primary care Patient 4: Peripheral artery disease Dr Terry McCormack Hambleton Richmond Whitby Clinical Commissioning Group Research Lead 01/05/2014 Delivering clinical research to
More informationUpdate on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics
Review Article Endocrinol Metab 2017;32:36-40 https://doi.org/10.3803/enm.2017.32.1.36 pissn 2093-596X eissn 2093-5978 Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More information2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?
Evolving Role of Coronary CTA in Primary Cardiovascular Disease Prevention: Are We There Yet? Ron Blankstein, M.D., F.A.C.C. Co-Director, Cardiovascular Imaging Training Program Associate Physician, Preventive
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationPredictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia
Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia Pãmela Rodrigues de Souza Silva, 1 Cinthia Elim Jannes, 1 Theo G. M. Oliveira, 1 Luz Marina Gómez
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationDIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO
DIAGNOSIS AND TREATMENT OF FH CHILDREN O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO DISCLOSURES Kowa MSD Pfizer Astrazeneca Synageva/Alexion OUTLINE Background
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationSection Editor Mason W Freeman, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationCottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?
Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAppendix F Simon Broome Diagnostic criteria for index individuals and relatives
Appendix F Simon Broome Diagnostic criteria for index individuals and relatives 1 SIMON BROOME DIAGNOSTIC CRITERIA FOR INDEX INDIVIDUALS (PROBANDS) 2 2 GENDER- AND AGE-SPECIFIC LDL-C CRITERIA FOR THE DIAGNOSIS
More informationParadim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie
Paradim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie Prof. G.Kees Hovingh, MD PhD MBA Dept. Vascular Medicine Academic Medical Center Amsterdam, the Netherlands Risk and profit
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationSmall dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study
Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationLIPID CLUB Rome, 2014
LIPID CLUB Rome, 2014 June the 6h 6th Hyperlipidaemia in FH Children Ornella Guardamagna University of Torino DICLOSURES Medpace Kowa DSMB member MSD, Pfizer, Synageva Investigator in industry funded trials
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More information